Navigation Links
deCODE genetics Announces Third Quarter 2007 Financial Results
Date:11/5/2007

1.3 million, compared to $42.9 million for the first nine months of 2006. Our research and development expense this year reflects the advancement of our drug development programs, the launch of our first three DNA-based tests for gauging individual risk of common diseases, and the acceleration of our gene and target discovery work in several major disease areas.

Selling, general and administrative expense for the third quarter of 2007 was $7.1 million, compared to $6.9 million for the 2006 period. For the first nine months of the year, SG&A expense was $19.4 million in 2007 and $16.6 million in 2006. The increases in SG&A expense year-on-year reflect the build- up of our diagnostics business as well as increased salary and stock-based compensation expense in the 2007 periods.

At September 30, 2007, the company had $118.6 million in cash, cash equivalents and investments, including restricted cash equivalents, compared to $152.0 million at December 31, 2006.

"The success of our gene discovery work is giving us a steady stream of novel targets for both diagnostics and therapeutics in major therapeutic areas. With the launch of deCODE AF(TM) and deCODE MI(TM), we have continued in the past quarter to expand our portfolio of DNA-based risk predisposition tests, offering new tools for focusing and improving disease prevention. More such products, including tests in glaucoma and other conditions, as well as a service through which individuals can begin to learn about their own genome, are on the way in the coming months," said Kari Stefansson, CEO of deCODE.

"In our drug development program targeting the leukotriene pathway for the prevention of heart attack, DG051 is now in a phase IIa trial that will aid us in dose selection for a larger Phase II study scheduled for early next year, and we expect to complete our bioequivalence analysis for our lead reformulation for DG031 before the end of 2007. With DG041, our Phase II anti- platelet compound, w
'/>"/>

SOURCE deCODE genetics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
4. Response Genetics Reports Second Quarter 2007 Financial Results
5. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... Aug. 14 Transgenomic, Inc. (the,"Company") (OTC Bulletin Board: ... 30, 2007. The Company,s financial results are,presented in the ... Company reported a net profit of $0.2 million or ... compared to a net loss of $0.4 million or,$0.01 ...
... Genetics, Inc.,(Nasdaq: RGDX ), today reported financial ... "The second quarter of 2007 was very ... public offering in June," said,Kathleen Danenberg, President and ... the recent developments that have since been announced. ...
... Summertime equals fun for a lot of,folks. ... (IBS), typical,summer fare could also mean aggravating their ... for IBS," has more on,what people with IBS ... IBS from,ruining their celebrations. Listen to this ...
Cached Biology Technology:Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Response Genetics Reports Second Quarter 2007 Financial Results 2Response Genetics Reports Second Quarter 2007 Financial Results 3Response Genetics Reports Second Quarter 2007 Financial Results 4Response Genetics Reports Second Quarter 2007 Financial Results 5Response Genetics Reports Second Quarter 2007 Financial Results 6Response Genetics Reports Second Quarter 2007 Financial Results 7Response Genetics Reports Second Quarter 2007 Financial Results 8
(Date:7/10/2014)... Florida , July 1, 2014 ... pave way for convenience and improved security: NXT-ID, Inc. (OTCBB: ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a ... pleased to announce that the second series of 30 second ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
(Date:7/10/2014)... -- According to the new market research ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... Finance), and Geography - Global Trends & Forecasts to ... Sensors Market is projected to cross $14.35 Billion by ... 2014 to 2020. Browse more than 78 ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Researchers at Burnham Institute for Medical Research at ... (a chain of amino acids) that specifically recognizes and ... was also shown to deliver diagnostic particles and medicines ... dramatically enhance both cancer detection and treatment. The work ...
... Mass. December 7, 2009 Biogen Idec (NASDAQ: ... fumarate) achieved key milestones in clinical trials for multiple ... the last patient was enrolled in the CONFIRM trial, ... evaluate the efficacy and safety of BG-12 as a ...
... Researchers from Yale University and Mirna Therapeutics, Inc., reversed ... occurring tumor suppressor microRNA. The study reveals that a ... role in cancer treatment, and provides hope for future patients ... cancers. "This is the first time anybody has shown a ...
Cached Biology News:Delivering medicine directly into a tumor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2
... anti-phospho-IRS1 (Tyr896) ... to amino acid region encompassing ... phospho-IRS1 (Tyr896). ... Quality Assurance: ...
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Biology Products: